Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 8 (August)

1. Effect of disrupted SOX18 transcription factor function on tumor growth, vascularization, and endothelial development.
   J Natl Cancer Inst, 98(15): 1060-7. [Abstract] [Full-text]
2. Shift work, light at night, and breast cancer on Long Island, New York.
   Am J Epidemiol, 164(4): 358-66. [Abstract] [Full-text]
3. Sentinel lymph nodes in breast cancer after 10 years: rethinking basic principles.
   Lancet Oncol, 7(8): 686-92. [Abstract] [Full-text]
4. Emerging use of nanoparticles in diagnosis and treatment of breast cancer.
   Lancet Oncol, 7(8): 657-67. [Abstract] [Full-text]
5. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network.
   Lancet Oncol, 7(8): 652-6. [Abstract] [Full-text]
6. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
   Lancet Oncol, 7(8): 633-43. [Abstract] [Full-text]
7. Estrogen receptors evolution in neoadjuvant aromatase inhibitor (AI) therapy for breast cancer in elderly women: stability of hormonal receptor expression during treatment.
   Am J Clin Oncol, 29(4): 385-8. [Abstract] [Full-text]
8. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
   Am J Clin Oncol, 29(4): 380-4. [Abstract] [Full-text]
9. Lobular neoplasia in breast core needle biopsy specimens is associated with a low risk of ductal carcinoma in situ or invasive carcinoma on subsequent excision.
   Am J Clin Pathol, 126(2): 310-3. [Abstract] [Full-text]
10. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients.
    Clin Chim Acta, 371(1): 191-3. [Abstract] [Full-text]
11. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
    Clin Chim Acta, 371(1): 112-6. [Abstract] [Full-text]
12. Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer.
    Clin Chim Acta, 371(1): 92-6. [Abstract] [Full-text]
13. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
    J Clin Oncol, 24(23): 3735-46. [Abstract] [Full-text]
14. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
    J Clin Oncol, 24(23): 3747-55. [Abstract] [Full-text]
15. Predictive and prognostic value of peripheral blood cytokeratin-19 mRNA-positive cells detected by real-time polymerase chain reaction in node-negative breast cancer patients.
    J Clin Oncol, 24(23): 3756-62. [Abstract] [Full-text]
16. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
    J Clin Oncol, 24(23): 3726-34. [Abstract] [Full-text]
17. Proteasome-independent down-regulation of estrogen receptor-alpha (ERalpha) in breast cancer cells treated with 4,4'-dihydroxy-trans-stilbene.
    Biochem Pharmacol, 72(5): 573-81. [Abstract] [Full-text]
18. Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells.
    Biochem Pharmacol, 72(5): 530-40. [Abstract] [Full-text]
19. TGF-beta in cancer and as a therapeutic target.
    Biochem Pharmacol, 72(5): 523-9. [Abstract] [Full-text]
20. PankoMab: a potent new generation anti-tumour MUC1 antibody.
    Cancer Immunol Immunother, 55(11): 1337-47. [Abstract] [Full-text]
21. Concordance among gene-expression-based predictors for breast cancer.
    N Engl J Med, 355(6): 560-9. [Abstract] [Full-text]
22. Do metallic ports in tissue expanders affect postmastectomy radiation delivery?
    Int J Radiat Oncol Biol Phys, 66(1): 305-10. [Abstract] [Full-text]
23. Effect of distance to radiation treatment facility on use of radiation therapy after mastectomy in elderly women.
    Int J Radiat Oncol Biol Phys, 66(1): 56-63. [Abstract] [Full-text]
24. Continuing evidence for poorer treatment outcomes for single male patients: retreatment data from RTOG 97-14.
    Int J Radiat Oncol Biol Phys, 66(1): 229-33. [Abstract] [Full-text]
25. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy.
    Int J Radiat Oncol Biol Phys, 66(1): 76-82. [Abstract] [Full-text]
26. The effects of intrafraction motion on dose homogeneity in a breast phantom with physical wedges, enhanced dynamic wedges, and ssIMRT.
    Int J Radiat Oncol Biol Phys, 66(1): 64-75. [Abstract] [Full-text]
27. Breast carcinoma specific antibody selection combining phage display and immunomagnetic cell sorting.
    Biochem Biophys Res Commun, 348(2): 550-9. [Abstract] [Full-text]
28. Cardiac dysfunction associated with trastuzumab.
    Expert Opin Drug Saf, 5(5): 619-29. [Abstract] [Full-text]
29. Statins and breast cancer: a smoking gun or guilt by association?
    Expert Opin Drug Saf, 5(5): 599-601. [Abstract] [Full-text]
30. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation.
    Br J Cancer, 95(4): 506-14. [Abstract] [Full-text]
31. Interactions between genes involved in the antioxidant defence system and breast cancer risk.
    Br J Cancer, 95(4): 525-31. [Abstract] [Full-text]
32. Genetic nurse counsellors can be an acceptable and cost-effective alternative to clinical geneticists for breast cancer risk genetic counselling. Evidence from two parallel randomised controlled equivalence trials.
    Br J Cancer, 95(4): 435-44. [Abstract] [Full-text]
33. The efficacy of breast MRI in predicting breast conservation therapy.
    J Surg Oncol, 94(3): 220-5. [Abstract] [Full-text]
34. Interpectoral approach to dissection of the axillary apex: an elegant and effective approach.
    J Surg Oncol, 94(3): 252-4. [Abstract] [Full-text]
35. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
    J Natl Cancer Inst, 98(16): 1108-17. [Abstract] [Full-text]
36. Rapid adaptation of a recombinant vesicular stomatitis virus to a targeted cell line.
    J Virol, 80(17): 8603-12. [Abstract] [Full-text]
37. Spot 14: A marker of aggressive breast cancer and a potential therapeutic target.
    Endocrinology, 147(9): 4048-55. [Abstract] [Full-text]
38. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
    Endocrinology, 147(9): 4056-66. [Abstract] [Full-text]
39. Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo.
    Toxicol Appl Pharmacol, 215(2): 168-78. [Abstract] [Full-text]
40. The R-Ras GTPase mediates cross talk between estrogen and insulin signaling in breast cancer cells.
    Mol Cell Biol, 26(17): 6372-80. [Abstract] [Full-text]
41. 7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors.
    J Med Chem, 49(17): 5352-62. [Abstract] [Full-text]
42. Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms.
    J Clin Oncol, 24(24): 3991-6. [Abstract] [Full-text]
43. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials.
    J Clin Oncol, 24(24): 3927-32. [Abstract] [Full-text]
44. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.
    J Clin Oncol, 24(24): 3919-26. [Abstract] [Full-text]
45. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.
    J Clin Oncol, 24(24): 3912-8. [Abstract] [Full-text]
46. Family history of breast cancer and short-term effects of childbirths on breast cancer risk.
    Int J Cancer, 119(6): 1468-74. [Abstract] [Full-text]
47. Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories.
    Int J Cancer, 119(6): 1403-11. [Abstract] [Full-text]
48. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer.
    Int J Cancer, 119(6): 1412-8. [Abstract] [Full-text]
49. Socioeconomic gradients in clinical stage at presentation and survival among breast cancer patients in the Stockholm area 1977-1997.
    Int J Cancer, 119(6): 1433-9. [Abstract] [Full-text]
50. UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells.
    Int J Cancer, 119(6): 1383-8. [Abstract] [Full-text]
51. Determinants of early distant metastatic disease in elderly patients with breast cancer.
    Am J Surg, 192(3): 317-21. [Abstract] [Full-text]
52. Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials.
    Expert Opin Biol Ther, 6(9): 951-62. [Abstract] [Full-text]
53. Carcinogen-induced DNA double strand break repair in sporadic breast cancer.
    J Surg Res, 135(1): 120-8. [Abstract] [Full-text]
54. Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine.
    Mol Pharmacol, 70(3): 1045-52. [Abstract] [Full-text]
55. Bayesian network to predict breast cancer risk of mammographic microcalcifications and reduce number of benign biopsy results: initial experience.
    Radiology, 240(3): 666-73. [Abstract] [Full-text]
56. Clinical breast examination in a comprehensive breast cancer screening program: contribution and cost.
    Radiology, 240(3): 650-5. [Abstract] [Full-text]
57. Mammographic density measured with quantitative computer-aided method: comparison with radiologists' estimates and BI-RADS categories.
    Radiology, 240(3): 656-65. [Abstract] [Full-text]
58. Computational exploration of the activated pathways associated with DNA damage response in breast cancer.
    Proteins, 65(1): 103-10. [Abstract] [Full-text]
59. A highly specific real-time RT-PCR method for the quantitative determination of CK-19 mRNA positive cells in peripheral blood of patients with operable breast cancer.
    Int J Cancer, 119(7): 1654-9. [Abstract] [Full-text]
60. Food patterns and risk of breast cancer: A factor analysis study in Uruguay.
    Int J Cancer, 119(7): 1672-8. [Abstract] [Full-text]
61. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma.
    Int J Cancer, 119(7): 1519-29. [Abstract] [Full-text]
62. Benign ovarian cysts and breast cancer risk.
    Int J Cancer, 119(7): 1679-82. [Abstract] [Full-text]
63. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study.
    Int J Cancer, 119(7): 1683-9. [Abstract] [Full-text]
64. Breast cancer risk in relation to abortion: Results from the EPIC study.
    Int J Cancer, 119(7): 1741-5. [Abstract] [Full-text]
65. Validation of the breast evaluation questionnaire for use with breast surgery patients.
    Plast Reconstr Surg, 118(3): 597-602. [Abstract] [Full-text]
66. Breast cancer diagnosis and prognosis in augmented women.
    Plast Reconstr Surg, 118(3): 587-93; discussion 594-6. [Abstract] [Full-text]
67. Preincisional paravertebral block reduces the prevalence of chronic pain after breast surgery.
    Anesth Analg, 103(3): 703-8. [Abstract] [Full-text]
68. Effects of young age at presentation on survival in breast cancer.
    BMC Cancer, 6: 194. [Abstract] [Full-text]
69. High incidence of familial breast cancer segregates with constitutional t(11;22)(q23;q11).
    Genes Chromosomes Cancer, 45(10): 945-9. [Abstract] [Full-text]
70. Dyskerin expression influences the level of ribosomal RNA pseudo-uridylation and telomerase RNA component in human breast cancer.
    J Pathol, 210(1): 10-8. [Abstract] [Full-text]
71. Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells.
    J Pathol, 210(1): 75-84. [Abstract] [Full-text]
72. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.
    J Pathol, 210(1): 3-9. [Abstract] [Full-text]
73. Cytomorphologic features of papillary lesions of the male breast: a study of 11 cases.
    Cancer, 108(4): 222-30. [Abstract] [Full-text]
74. Fine-needle aspiration cytology of mammary adenomyoepithelioma: a study of 12 patients.
    Cancer, 108(4): 250-6. [Abstract] [Full-text]
75. Emerging drugs to replace current leaders in first-line therapy for breast cancer.
    Expert Opin Emerg Drugs, 11(3): 489-501. [Abstract] [Full-text]
76. Family history of breast cancer as a risk factor for ovarian cancer in a prospective study.
    Cancer, 107(5): 1075-83. [Abstract] [Full-text]
77. Multicenter evaluation of the breast lesion excision system, a percutaneous, vacuum-assisted, intact-specimen breast biopsy device.
    Cancer, 107(5): 945-9. [Abstract] [Full-text]
78. A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach.
    Cancer, 107(5): 935-44. [Abstract] [Full-text]
79. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation.
    Cancer, 107(5): 885-92. [Abstract] [Full-text]
80. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?
    Clin Chem, 52(9): 1693-700. [Abstract] [Full-text]
81. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Cancer, 107(5): 950-8. [Abstract] [Full-text]
82. Advances and surgical decision-making for breast reconstruction.
    Cancer, 107(5): 893-907. [Abstract] [Full-text]
83. WISP-2/CCN5 is involved as a novel signaling intermediate in phorbol ester-protein kinase Calpha-mediated breast tumor cell proliferation.
    Biochemistry, 45(35): 10698-709. [Abstract] [Full-text]
84. Expression of xenobiotic and steroid hormone metabolizing enzymes in human breast carcinomas.
    Int J Cancer, 119(8): 1785-91. [Abstract] [Full-text]
85. Tobacco smoking, NAT2 acetylation genotype and breast cancer risk.
    Int J Cancer, 119(8): 1961-9. [Abstract] [Full-text]
86. Observations on the presence of E domain variants of estrogen receptor-alpha in the breast tumors.
    J Surg Oncol, 94(4): 332-7. [Abstract] [Full-text]
87. Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer.
    J Surg Oncol, 94(4): 281-6. [Abstract] [Full-text]
88. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
    J Clin Oncol, 24(25): 4107-15. [Abstract] [Full-text]
89. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment.
    J Clin Oncol, 24(25): 4100-6. [Abstract] [Full-text]
90. Molecular mechanism of inhibitory aryl hydrocarbon receptor-estrogen receptor/Sp1 cross talk in breast cancer cells.
    Mol Endocrinol, 20(9): 2199-214. [Abstract] [Full-text]
91. Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells.
    Mol Endocrinol, 20(9): 2020-35. [Abstract] [Full-text]
92. Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase.
    Mol Endocrinol, 20(9): 2010-9. [Abstract] [Full-text]
93. Antitumor agents. 254. Synthesis and biological evaluation of novel neo-tanshinlactone analogues as potent anti-breast cancer agents.
    J Med Chem, 49(18): 5631-4. [Abstract] [Full-text]
94. Synthesis, characterization, and biological evaluation of M(I)(CO)3(NNO) complexes (M = Re, 99mTc) conjugated to 2-(4-aminophenyl)benzothiazole as potential breast cancer radiopharmaceuticals.
    J Med Chem, 49(18): 5408-10. [Abstract] [Full-text]
95. Time spent in the United States and breast cancer screening behaviors among ethnically diverse immigrant women: evidence for acculturation?
    J Immigr Minor Health, 8(4): 347-58. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.